Mito Drug advances to FDA Phase IIa Trials

Penwest Pharmaceuticals has been working on a new mito drug – A0001 – for the treatment of mitochondrial diseases. The Phase 1b Trial of the drug under FDA guidelines went well and they are moving the drug into the next phases of the trial, as they move forward on orphan drug status and closer to an FDA approved medication for mitochondrial disease! The link will take you to the press release article for more information. It is great that there is some attempts being made to make medications to help mito!

Penwest Announces Results of Phase Ib Trial of A0001